Could a new weight loss approach have longer term benefits than GLP-1s?

The latest episode of the DDW 'In Conversation With' series is available to listen to below. This week, Bruno Quinney speaks to Vincent Marion, Scientific Founder and President of AdipoPharma. AdipoPharma is a biotech leveraging research on insulin resistance and adipose tissue biology, developing a new treatment for metabolic diseases. Vincent discusses what makes AdipoPharma's lead asset different from GLP-1s, why findings into fat tissue dysfunction have been less explored in drug development, and how AdipoPharma is competing in an industry where GLP-1s are becoming increasingly accessible.   You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.